Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Andreshak

Orthopaedic Surgery Sylvania, OH Medical Doctor

NPI 1447364773 CMS profile 110401

7640 Sylvania Ave, Ste. B, Sylvania, OH 43560

Open in the dashboard

General payments

$292,451

555 records reported · program years 2019–2025

Research payments

$3,150

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Andreshak of Sylvania, OH is reported in the CMS Open Payments database as having received $292,451 across 555 general payments and $3,150 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,000 66
2024 General $47,854 76
2023 General $54,633 93
2022 General $38,240 80
2021 General $39,417 68
2020 General $31,973 59
2020 Research $3,150 1
2019 General $53,333 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Andreshak
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Thomas Andreshak were reported at $27,000. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Thomas Andreshak Orthopaedic Surgery median Middle half National median
2019 $53,333 $644 $140–$2,844 $163
2020 $31,973 $312 $75–$1,860 $114
2021 $39,417 $520 $117–$2,495 $132
2022 $38,240 $598 $128–$2,731 $149
2023 $54,633 $461 $128–$2,264 $160
2024 $47,854 $497 $134–$2,475 $164
2025 $27,000 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $196,129 285 payments
  2. Medtronic USA, Inc. $74,742 143 payments
  3. RTI Surgical, Inc. $11,101 8 payments
  4. Axis360 Surgical Inc $3,977 4 payments
  5. Intrinsic Therapeutics $1,425 9 payments
  6. Amgen Inc. $705 14 payments
  7. Globus Medical, Inc. $533 7 payments
  8. Smith+Nephew, Inc. $506 6 payments
  9. Stryker Corporation $377 8 payments
  10. Providence Medical Technology, Inc. $330 5 payments
  11. Other $2,626 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $227,950 44 payments
  2. Consulting Fee $34,662 11 payments
  3. Food and Beverage $17,843 457 payments
  4. Travel and Lodging $10,770 40 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,200 1 payment
  6. Entertainment $19 1 payment
  7. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. KYPHON EXPRESS II KYPHOPAK TRAY $114,738 145 payments
  2. OSTEOCOOL RF ABLATION Neuro Pain (includes Interventional) $46,211 27 payments
  3. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $27,899 39 payments
  4. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $27,673 84 payments
  5. OSTEOCOOL RF ABLATION SYSTEM $24,313 37 payments
  6. INTELLIS ADAPTIVESTIM $21,005 27 payments
  7. OSTEOCOOL RF ABLATION Neuro Pain (includes Interventional) $5,661 3 payments
  8. COFLEX INTERLAMINAR TECHNOLOGY, 10MM $5,380 2 payments
  9. Coflex $4,922 3 payments
  10. BARRICAID ACD (ANNULAR CLOSURE DEVICE) $1,425 9 payments
  11. Other $10,862 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Globus Medical, Inc. $3,150 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,247

Median for Orthopedic Surgery: 203

Drug cost

$64,821

Median for Orthopedic Surgery: $1,433

Branded share of claims

17.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tymlos Abaloparatide Brand 19 $51,084
Pregabalin Generic 172 $5,413
Diclofenac Sodium Generic 113 $1,516
Celecoxib Generic 55 $1,216
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 118 $1,085
Tizanidine Hcl Generic 170 $1,031
Gabapentin Generic 54 $1,001
Meloxicam Generic 92 $545
Tramadol Hcl Generic 80 $346
Acetaminophen-Codeine Acetaminophen With Codeine Brand 24 $294

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$259,248

Of which drugs: $64,983

Medicare patients

339

Average age 75

Services billed

4,999

206 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 37%
Diabetes 30%
Ischemic heart disease 27%
Chronic kidney disease 25%
Depression 25%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 41 3,300 $64,946

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Tymlos
  • Radius Health, Inc. $21
$21 19 —
EVENITY
  • Amgen Inc. $8
$8 — —
Prolia
  • Amgen Inc. $8
$8 — 3,300

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

556 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record